Article Text

PDF
Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy
  1. P Melacini,
  2. B J Maron,
  3. F Bobbo,
  4. C Basso,
  5. B Tokajuk,
  6. M Zucchetto,
  7. G Thiene,
  8. S Iliceto
  1. Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy; The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA; Institute of Pathological Anatomy, University of Padua Medical School, Padua, Italy
  1. Correspondence to:
    Dr B J Maron
    Minneapolis Heart Institute Foundation, 920 East 28th Street, Suite 60, Minneapolis, MN 55407, USA; hcm.maron{at}mhif.org

Abstract

Objective: To determine the efficacy of pharmacological treatment in the prevention of sudden cardiac death in hypertrophic cardiomyopathy (HCM).

Design: Clinical outcome was assessed retrospectively in 293 patients with HCM, including 173 who were taking cardioactive medications.

Setting: Department of Cardiology, University of Padua, Padua, Italy; a tertiary HCM Centre.

Interventions: Medical treatment with β blockers, verapamil, sotalol and amiodarone.

Main outcome measure: HCM-related sudden cardiac death.

Results: 17 of 173 (10%) patients died suddenly or had aborted cardiac arrest, while being treated continuously with drugs having antiarrhythmic properties, over a period of 62 (56) months. Sudden death occurred in 20% of patients administered amiodarone (6/30), 9% each of patients taking verapamil (4/46) or β blockers (7/76), and 0% of those taking sotalol (0/21). Patients taking cardioactive drugs (n = 173) and those without pharmaceutical therapy (n = 120) did not differ with respect to sudden death mortality.

Conclusion: Medical treatment is not absolutely protective against the risk of sudden death in HCM. The present data inferentially support the use of the implantable defibrillator as the primary treatment choice for prevention of sudden death in high-risk patients with HCM.

  • HCM, hypertrophic cardiomyopathy
  • ICD, cardioverter defibrillator

Statistics from Altmetric.com

Footnotes

  • Funding: This study was supported by the Italian Ministry for Scientific and Technologic Research (MURST-COFIN 2002 prot 2002065749 002).

  • Competing interests: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.